With our cutting-edge in silico drug discovery capabilities 👉 https://www.pharmidex.com/In-silico Pharmidex is committed to accelerating the development of novel therapies targeting GLP-1 receptors, a promising path in the fight against obesity and type 2 diabetes. By combining our in silico expertise, including molecular docking, virtual screening and structure-based design, with our well-established in vivo obesity models, we offer a powerful, integrated platform to uncover and validate new therapeutic candidates more efficiently. Whether you're a pharma company, CRO, biotech, or academic institution, Pharmidex is ready to collaborate and support your discovery efforts from computational predictions to real-world preclinical validation. 🤝 Let’s combine strengths and accelerate innovation in metabolic disease research to improve human health globally.

We’re excited to share that Janette Robertson (Business Development Manager) and Professor Mo Alavijeh (Managing Director) will attend the SMR Women’s Health Meeting at Friends House, London. They look forward to meeting attendees and discussing collaboration opportunities in drug discovery and development, especially in women’s health. 📅 More info: https://www.smr.org.uk/Meetings/20250617/ 🤝 Let’s connect in London!